Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 835-841

  Rubenstein, Marvin ^a,b,c   Hollowell, Courtney M P ^b   Guinan, Patrick ^a,b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Prostate cancer; Therapy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTISENSE OLIGONUCLEOTIDE; GAMMA INTERFERON; LIPOFECTIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR; TUMOR VACCINE; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MESSENGER RNA;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRAIN LNCAP; CELL SURFACE; HLA SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL DIFFERENTIATION; DRUG ANTAGONISM; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIGENS, SURFACE; CELL DIFFERENTIATION; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INTERFERON-GAMMA; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84866280126     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9977-x     Document Type: Article

References (23)

1. www.oncogenex.ca/.
2. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA. 1988;85:5011-5.
3. Felsenfeld G, Miles HT. Formation of a three-stranded polynucleotide molecule. J Am Chem Soc. 1957;79:2023-4.
4. Durland RH, Kessler DJ, Hogan M. Antiparallel triplex formation at physiological pH. In: Wickstrom E, editor. Prospects for antisense nucleic acid therapy of cancer and AIDS. New York: Wiley-Liss; 1991. p. 219-26.
5. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Clin Pharmacol. 2006;28:515-8.
6. Rubenstein M, Tsui P, Guinan P. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate cancer. Med Oncol. 2007;24: 372-8.
7. Rubenstein M, Tsui P, Guinan P. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparisons between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel. Med Oncol. 2009;26:124-30.
8. Rubenstein M, Tsui P, Guinan P. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses. 2005;65:905-7.
9. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Med Oncol. 2007;24:189-96.
10. Rubenstein M, Tsui P, Guinan P. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity towards proteins associated with autocrine regulated growth and bcl-2. Med Oncol. 2008; 25:182-6.
11. Rubenstein M, Guinan P. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of Bcl-2 in LNCaP cells. In Vivo. 2010;24:489-93.
12. Rubenstein M, Hollowell CMP, Guinan P. Does the prostate retain an endogenous antiviral defense system suggesting a past viral etiology for cancer? Med Hypoth. 2011;76:368-70.
13. Lubaroff DM, Konety BR, Link BK, et al. Outcomes from a phase I trial of an adenovirus/PSA vaccine for prostate cancer. J Urol. 2008;179 Suppl:184, Abstract 526.
14. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recominant gamma interferon induced HLA-DR expression on cultered human keratinocytes. J Invest Derm. 1984;83:88-90.
15. Msujimoto M, Yip YK, Vilcek J. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J Immunol. 1986;136:2441-4.
16. Rubenstein M, Mirochnik Y, Chow P, Guinan P. Antisense oligonucleotide intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol. 1996;62:194-200.
17. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B, Gleave M. Novel bispecific antisense oligonucleotides inhibiting both Bcl-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc AACR. 2004;45:2930a.
18. Takahara K, Muramaki M, Li D, Cox ME, Gleave ME. Insulinlike growth factor-binding protein-5 (IGFBP5) supports prostate cancer cell proliferation. J Urol. 2009;181:184a.
19. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Med Oncol. 2007;24:189-96.
20. Mirochnick Y, Rubenstein M, Guinan P. Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles. J Drug Target. 2007;15:342-50.
21. Rubenstein M, Anderson KM, Tsui P, Guinan P. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer. Med Hypoth. 2006;67:1375-80.
22. Lee B-S, Fujita M, Ljubimova JY, Holler E. Delivery of antisense oligonucleotides and transferring receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid. Proc AACR. 2004;45:647a.
23. Santhakumaran L, Thomas T, Thomas TJ. Nanoparticle formation in an antisense oligonucleotide by polyproplin-imine dendrimers: facilitation of cellular uptake and intracellular stability. Proc AACR. 2004;45:2938a.